with high values of body mass index given buttock injections. This may be because the vaccine is injected into fat rather than muscle in these individuals and is only poorly presented to the immune system, so eliciting little immune response. With injections into the arm and using the EIA method of antibody measurement, the response rate in this population is around 99%. Thus routine antibody testing after immunisation is probably unnecessary.
contact. Three doses of 20 jg of vaccine are given at zero, one, and six months and the antibody response is measured three months later. Results were analysed to seek for associations with the antibody response. At the time of analysis, 2739 people had started vaccination and 1067 had completed the course and had a measurement of antibody response. Vaccine injections were initially into the buttock and later into the arm; measurement of antibody levels was initially by radioimmunoassay (RIA) and later by enzyme immunoassay (EIA). A positive antibody response was defined as a positive/negative ratio of > 10 for RIA or a level of > 10 mIU/ml for EIA. Associations between antibody response and other variables were tested by x2 and a multiple logistic regression analysis was undertaken to examine the effects of variables in combination. The overall antibody response rate was 95%. Men with high values of body mass index given buttock injections. This may be because the vaccine is injected into fat rather than muscle in these individuals and is only poorly presented to the immune system, so eliciting little immune response. With injections into the arm and using the EIA method of antibody measurement, the response rate in this population is around 99%. Thus routine antibody testing after immunisation is probably unnecessary.
Hepatitis B immunisation, using plasma derived vaccine, is a safe and effective means of protecting against hepatitis B infection in groups of individuals at risk.' 2 In 1987 recombinant hepatitis B vaccine was licensed in the United Kingdom. Immunisation with either preparation is recommended for health care workers, especially those at risk of contamination with blood or other body fluids in the course of their work. 3 The seroconversion rate after a course of three injections of vaccine is generally high.45 The proportion of non-responders increases with age4" and has been reported to be higher when the vaccine is given into the buttock than when it is given into the upper arm.6 Some non-responders may respond to a fourth dose of vaccine57 but there is apparently a genetically determined group of persistent non-responders. 8 A programme of hepatitis B immunisation for staff began in Hampstead Health Authority soon after the plasma derived vaccine was licensed in the United Kingdom. The antibody response to the vaccine was measured as part of this programme and this has allowed an analysis of the variables related to the response rate to be undertaken. This paper describes the immunisation programme and presents the results of the analysis of the antibody response. The immunisation programme is undertaken by the district occupational health unit. Since 1987 the programme has been computerised, using a microcomputer in the occupational health unit and dBase III + software (Ashton-Tate). Information was extracted from this database for analysis.
The immunisation course consists of three doses, each of 20 ,g, of vaccine at zero, one, and six months. Initially, injections were given into the buttock (aiming for the gluteal muscles) but this practice was changed after reports of lower response rates with injections at this site.6 Thereafter, the vaccine was injected into the upper arm (aiming for the deltoid muscle). Thus some people had mixed site courses of vaccine. The vaccine used was a plasma derived type for most of the period of the programme analysed here but a recombinant type was used in a few subjects near the end of the period and has now become the routine type used.
Anti-HBs antibody was measured before immunisation in the early days of the programme but this practice was discontinued because so few people (< 10o) in this population had pre-existing antibodies. In all individuals antibodies were measured three months after the third dose of vaccine. The initial method used to estimate anti-HBs levels was a commercially available radioimmunoassay (RIA) (Abbott Laboratories). For organisational reasons, the department measuring the antibody levels changed in the summer of 1987 and the new department used an enzyme immunoassay (EIA) method for estimating anti-HBs (Behring). All the subjects who had antibodies tested by the EIA method had received injections into the arm.
INFORMATION FOR THE ANALYSIS
Subjects included in the analysis were those who had received three doses of vaccine (at zero, one, and six months) and who had had a blood sample taken for estimation of anti-HBs about 12 weeks (range 4-26 weeks) after the third injection. As at August 1988 2739 subjects had received at least one vaccine dose, 2128 had received three doses, and 1067 had received three doses and had a measurement of antibody response.
Information recorded for each subject included age, sex, height, weight, site of injections, postimmunisation anti-HBs levels, and method of antibody estimation for each recorded level. The Quetelet index of body mass (weight/height2) was calculated for each subject and used in the analysis.9
For antibodies measured by RIA, a positive-negative ratio of > 10 was considered as a positive response and of < 10 as a negative response. For EIA measurements antibody levels of > 10 mIU/ml were considered a positive response and those < 10 mIU/ ml were considered a negative response.
ANALYSIS
Univariate analysis was performed to determine differences in age and Quetelet index for positive and negative antibody responders and the effect on antibody response, positive or negative, of the variables sex, site of vaccine injection, and method of measuring anti-HBs. The significance of differences was tested using the Mann-Whitney test or x2 test as appropriate.
A multiple logistic regression analysis (using the GLIM statistical package) was then performed to examine the relation between the proportion of positive antibody responses and the same variables in combination.'" Logistic regression models were fitted separately for all the data, for antibody results by RIA only, and for antibody results by EIA only. In each case the model for the contributions of the different variables that best explained the antibody results was sought. The analysis was confined to subjects with complete data for all the variables and who had received injections at only one site, whether buttock or arm.
Results
In the 1067 subjects included in the analysis the overall response rate (anti-HBs > 10 positivenegative ratio or > 10 mIU/ml) was approximately 9500. The response rate was significantly higher when anti-HBs was estimated by the EIA rather than the RIA method (table 1). The response rate did not differ between men and women with either method of testing (table 2) . The response rate tended to be higher in those who had received injections in the arm rather than the buttock (excluding those who had had mixed site injections), although the difference was not significant at the 10% level (table 3) . For both testing methods, responders were significantly younger than non-responders and had significantly lower values of Quetelet index (table 4) . The number of subjects who received the recombin- ant vaccine (all of whom had antibody levels measured by EIA) was too small for separate analysis but there was no suggestion of a response rate differing between the two types of vaccine. The logistic regression analysis was performed on 891 subjects with complete data for all variables: 250 with antibodies tested by RIA and 641 with antibodies tested by EIA. The variation in proportion of positive antibody responses was significantly reduced by taking into account the combination of the one way effects of the measured variables, except when only considering antibody results by EIA where there was only one site of injection (the arm). For all the data, and for those including only antibodies measured by RIA, further significant reductions in variation were produced by adding the two way interactions of sex injection site and Quetelet index injection site. There was a significant effect of age and antibody testing method which was uniform for all levels of sex, injection site, and Quetelet index. But the influence of injection site on the response differed for the two sexes and for different levels of Quetelet index. Figure 1 shows the effect of age on the proportion of positive responders for the RIA testing method only, predicted from the best fitting model. Figure 2 illustrates the predicted effects of the interactions between sex, injection site, and Quetelet index on the proportion of positive responders at the median age of 27. For arm injections, the response is slightly higher for women than men, whereas for buttock injections, men have a higher rate of response. The rate of response declines gradually with increasing Antibody response has been reported to be better in women,4 though not all investigators agree.5 We found no overall effect of sex on antibody response but a significant interaction with injection site, such that women were less likely to respond than men if the vaccine was given into the buttock with the reverse if the vaccine was given into the arm. This interaction may help to explain the discrepancy between the results of other investigators. Despite reports of a poorer response to injections in the buttock,6 recent authors have reported series of immunisations into the buttock with good response rates.57 We were able to look at the effect of injection sites within our series and have found that the effect of injection site is mainly in subjects with a high Quetelet index (fig 2) . This interaction has not previously been taken into account. The probable explanation for the interaction is that in obese people buttock injections are intra-adipose rather than intramuscular. The different distribution of adipose tissue in men and women may explain why this effect seems to be especially evident in women (see fig 2) . Presumably the vaccine is only poorly presented to the immune system from the adipose tissue and so elicits little immune response.
Using our present antibody testing method, and injecting vaccine into the arm, our non-response rate is in the order of 10%. This suggests that routine testing of postimmunisation antibody levels is probably unnecessary. 
